Wund(er)heilung mit Amnion – DGFG erhält deutschen Wundpreis 2021
Ausschreibung DGNI-Pflege- und Therapiepreis 2022
Ausschreibung: Otsuka Team Award Psychiatry+ 2021
BGW-Gesundheitspreis 2022: Gute Praxis aus der Altenpflege gesucht!
Aktionsbündnis Patientensicherheit vergibt Deutschen Preis für Patientensicherheit 2021 an herausragende…
20.-22.01.2022 online: ANIM: NeuroIntensivmediziner diskutieren neue Erkenntnisse zu COVID-19
8.-10. September 2021: Weimar Sepsis Update 2021 – Beyond the…
13.09. – 18.09.2021: Viszeralmedizin 2021
24.06. – 26.06.2021: 27. Jahrestagung der Deutschen Gesellschaft für Radioonkologie
17.06. – 19.06.2021: 47. Jahrestagung der Gesellschaft für Neonatologie und…
Merck Sharp & Dohme (Europe), Inc. withdraws its marketing authorisation application for Janacti (sitagliptin and pioglitazone) and related trade names
London, UK, (November 14, 2011) – The European Medicines Agency has been formally notified by Merck Sharp & Dohme (Europe), Inc. of its decision to withdraw its application for a centralised marketing authorisation for the medicine Janacti (sitagliptin and pioglitazone) and related trade names, 100/30 mg and 100/45 mg fixed-dose combination tablets. Janacti was intended to be used for the treatment of adult patients with type II diabetes mellitus.
The application for the marketing authorisation for Janacti was initially submitted to the Agency on 31 May 2011. At the time of the withdrawal it was under evaluation by the Committee for Medicinal Products for Human Use.
In its official letter, the company stated that they are basing their decision to withdraw the application on a review of the regulatory and commercial prospects for the fixed-dose combination product. There are currently no ongoing clinical trials with Janacti.
More information about Janacti and the stage of the scientific assessment procedure at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency’s website after the next CHMP meeting on 14-17 November 2011.
European Medicines Agency, 14.11.2011 (tB).